Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Total Liabilities: 2017-2025

Historic Total Liabilities for Arcus Biosciences (RCUS) over the last 8 years, with Sep 2025 value amounting to $538.0 million.

  • Arcus Biosciences' Total Liabilities fell 26.80% to $538.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.0 million, marking a year-over-year decrease of 26.80%. This contributed to the annual value of $665.0 million for FY2024, which is 5.06% up from last year.
  • As of Q3 2025, Arcus Biosciences' Total Liabilities stood at $538.0 million, which was up 2.28% from $526.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Total Liabilities registered a high of $750.4 million during Q4 2021, and its lowest value of $270.3 million during Q1 2021.
  • Over the past 3 years, Arcus Biosciences' median Total Liabilities value was $633.0 million (recorded in 2023), while the average stood at $623.5 million.
  • Per our database at Business Quant, Arcus Biosciences' Total Liabilities soared by 661.36% in 2021 and then decreased by 26.80% in 2025.
  • Over the past 5 years, Arcus Biosciences' Total Liabilities (Quarterly) stood at $750.4 million in 2021, then fell by 14.32% to $643.0 million in 2022, then decreased by 1.56% to $633.0 million in 2023, then rose by 5.06% to $665.0 million in 2024, then decreased by 26.80% to $538.0 million in 2025.
  • Its last three reported values are $538.0 million in Q3 2025, $526.0 million for Q2 2025, and $625.0 million during Q1 2025.